Efi Kontou

#JPM26 was the best yet for Enveda - presenting at a packed house at the conference, where we discussed our incredible 𝗣𝗵𝗮𝘀𝗲 𝟭𝗯 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗶𝗻 𝗮𝘁𝗼𝗽𝗶𝗰 𝗱𝗲𝗿𝗺𝗮𝘁𝗶𝘁𝗶𝘀, and building a 𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗯𝗶𝗼𝘁𝗲𝗰𝗵. We've been working hard behind the scenes to get us to where we are today, with 𝟰 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗽𝗿𝗼𝗴𝗿𝗮𝗺𝘀 𝗶𝗻 𝗷𝘂𝘀𝘁 𝟲 𝘆𝗲𝗮𝗿𝘀 in the largest indications, and we are just getting started. You might even have caught one of our ads for our 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀 in 𝗮𝘁𝗼𝗽𝗶𝗰 𝗱𝗲𝗿𝗺𝗮𝘁𝗶𝘁𝗶𝘀 and 𝗼𝗯𝗲𝘀𝗶𝘁𝘆! Patients need new and differentiated options and can't wait! Stay tuned! #JPMHC26

Six years ago, this was a thesis. Today, it’s clinical data. Next week at #JPM26, we’ll be sharing progress that reflects years of deliberate choices coming together. Our oral therapy for atopic dermatitis, ENV-294, has generated compelling Phase 1b data showing strong clinical activity and a clean safety profile in one of the largest and most competitive categories in medicine. The signal supports best-in-disease potential and represents exciting clinical proof of the thesis Enveda was built on. ENV-294 matters not just because it is a strong program, but because it is the output of a system we have been building since day one. A company singularly focused on discovering, developing, and delivering breakthrough medicines with the potential to not just capture, but create markets. We now have three assets in the clinic: ENV-294 in atopic dermatitis and asthma, now in Phase 2a with a Jak-like efficacy and a Dupi-like safety profile ENV-308 for obesity, with the first patient dosed in Phase 1, a “statin for obesity”, engineered for a post-GLP1 world ENV-6946 for IBD, bringing together clinically validated biology across TNFa, TL1A, IL23, and NLRP3, via a single novel-target delivered in a convenient pill With additional INDs expected in 2026, Enveda is now a multi-asset clinical-stage company with a highly concentrated set of upcoming catalysts. Looking ahead over the next several quarters, this foundation provides both momentum and resilience. It positions us to move quickly, take meaningful swings, and continue building a generational company that endures. We look forward to sharing more next week in San Francisco. #JPM26 #ENV294 #ENV308 #DrugDiscovery #ClinicalTrials #Biotech #Enveda #LearningFromLife #RevolutionizingImmunology #RevolutionizingObesity

If you know, you know... #JPM26 is going to be a big one for us: - 4 Clinical Programs: #AtopicDermatitis, #IBD, #Asthma, and #Obesity - Incredible Phase 1b results for our first-in-class oral for atopic dermatitis (ENV-294) - Deep pipeline of next-gen medicines Let's meet! See you there!

Η Βενεζουέλα, η Ελλάδα και η «βίαιη ενηλικίωση» της νέας εποχής iefimerida.gr/kosmos/benezoy… By @ArisVourvoulias

How we built a unicorn from seed in 5 years… There are no secrets, but purpose, pace, and an incredible team certainly help. “We’re combining ancient ancestral wisdom with the power of nature’s chemistry with modern AI and drug discovery,” Colluru said. “We’re standing on the shoulders of maybe the giant, which is Mother Nature.” Read more by @damiangarde in @business about how we raised our Series D, advanced our lead candidate in atopic dermatitis to Phase 1b, and brought on a pharma legend Mikael Dolsten as we prepare to enter more programs in the clinic this year... and stay tuned for more. #Unicorn #Startups #AI #DrugDiscovery #Nature

Biotech’s latest unicorn Enveda want to use AI to scour thousands of plants for potential medicinal breakthroughs bloomberg.com/news/articles/…

@sanofi is a global leader in the treatment of atopic dermatitis and other inflammatory diseases. Their investment supports the promise of using AI to learn from life’s chemistry — not just in accelerating new medicines but in expanding our fundamental understanding of the natural world. ENV-294 has the potential to transform  the treatment paradigm for inflammatory diseases. This first-in-class therapy targets biology no other drug has been able to reach—now in the final stages of Phase I clinical trials. With imminent Phase 2 trials for #atopicdermatitis and #asthma, we're one big step closer to changing millions of  lives. This is just the beginning. #learningfromlife #biotech #AI #pharma

So proud 🤩

Exciting news! Enveda Biosciences has been named one of LinkedIn's Top Startups in Denver! Since 2019, we've grown to nearly 250 strong, with roots in Boulder. Our mission: translating nature into medicine. Thanks to our incredible team—medicinal chemists, biologists, AI experts, and more! bit.ly/4eHK6ED

"5 years ago, in 2019, Enveda was an idea, an old laptop, and me in a small 2-bedroom apartment in Florida, with no tech and no IP," says our CEO, @ViswaColluru. Watch how Enveda grew to a 200+ employee AI-powered drug discovery leader. cbsnews.com/video/a-moment… #AI #Biotech

Thank you to the team at @beondeck for naming us among their Top Companies for the second year in a row! We're grateful for the recognition of our progress -- and we are just getting started! We've built a first-in-class drug discovery platform, moved into our new HQ, built a strong company culture across 2 continents, and are now in the final stages of prepping our multiple lead candidates for clinical trials. Stay tuned for more! tinyurl.com/2k25n4sr

At Enveda, we define "Global Health" as encompassing both human and planetary health, and so we are thrilled to have our work featured in this Reuters series as part of the Global Health Summit in Geneva, Switzerland. Check out the video to learn more! reuters.com/plus/acumen/gl…

Our lab is excited to share a preprint on localizing the site of structural modifications for small molecules using ModiFinder. For those using Molecular Networking, we hope this will speed up the process of structural elucidation when propagating from known compounds.

@tilmweber @MatissMaleckis @CorreLabo @PabloCruzMoral1 @DTUBiosustain @cemist_dtu Congratulations Matiss and Tilmann 🎉🎉

📣We are looking for an experienced clinical Metabolomics scientist at ⁦@envedabio⁩! linkedin.com/jobs/view/3825…

We're proud to announce the formation of our Therapeutic Advisory Board, chaired by Nicholas A. Saccomano Ph.D., which will help guide our expanding pipeline and clinical trials. Read on to learn more 🧵👇

Start-Up Academy X Venture&Wine 🔥 To kick off Start-Up Academy 2024, our alumni came to share their personal experiences and learnings: 👉 Understanding of the ecosystem 👉 Strong knowledge 👉Networking A huge thanks to them! ✨ Sign-Up for 2024:   rebbls.dk/startupacademy 👀

Join us Thursday, Jan 11 at the main stage of #JPM24 as Founder & CEO @viswacolluru presents exciting new preclinical data comparing Enveda's lead asset to blockbuster anti-inflammatory therapies, plus pipeline and platform updates. Don't miss it!

Με μεγάλη χαρά σας παρουσιάζω το πόντκαστ μου «Do it Like»! Το «Do it Like» είναι ένα podcast για τις εξαιρέσεις και τους εξαίρετους της ιστορίας. Ep 1: Do it Like #Singapore: #Οικονομία Ακούστε το επεισόδιο και διαβάστε εδώ την περίληψη του podcast: pod.gr/do-it-like/

We're excited to announce the six former Venture Lab start-ups that have made it into our Venture House Program! Congratulations to TriptoBIO, Agrobiomics, Matr Foods, HHC medical, SOLID Therapeutics, and FimmCyte - our first industry-sponsored Venture House company - who will make up our third Venture House cohort.🚀 Learn more: bit.ly/3sFmugK